Biotech firms aim to engineer foods that won’t trigger allergic reactions

More than 22 million Americans suffer from food allergies, a condition that drives a $370.8 billion annual economic burden and forces many into strict avoidance. New research shows that tolerance depends on recognizing certain protein fragments, suggesting a vaccine-like approach could re-educate the immune system. At Stanford, Beth Sattely is decoding these plant-derived signals to understand how tolerance develops.

Parallel efforts include IngateyGen’s CRISPR removal of peanut allergen genes and Kansas State’s gene-edited wheat with reduced gluten immunogenicity. Ukko combines AI-guided protein redesign with gene editing to blur allergenic epitopes while preserving function, and its peanut candidate UKK-0018 has begun safety trials, with early data due in 2027. The advances hint at a future where crops are bred to be inherently non-allergenic, though financial and market hurdles remain.